iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Robert Goodman, M.D., has been named to iCAD’s Board of Directors. Dr. Goodman brings nearly 50 years of clinical experience, along with extensive academic and leadership credentials. He is the first radiation oncologist to serve on iCAD’s multidisciplinary Board.
Robert Goodman, M.D. (Photo: Business Wire)
“Dr. Goodman’s impressive clinical background, coupled with his business leadership experience and prestigious academic affiliations, will make him an invaluable addition to iCAD’s Board of Directors,” said Ken Ferry, Chief Executive Officer of iCAD, Inc. “As a highly regarded member of the radiation oncology community, we look forward to Dr. Goodman’s guidance and insight as we continue to grow and strengthen the Xoft business.”
Dr. Goodman is a renowned radiation oncologist who is credited with pioneering the use of radiotherapy to treat women with breast cancer. He has served as the Pancoast Professor and Chair of the Department of Radiation Oncology at the University of Pennsylvania and Chair of Radiation Oncology at St. Barnabas Medical Center. Additionally, he served two years as Acting Executive Director of the Hospital of the University of Pennsylvania. Dr. Goodman has also held faculty appointments at several prestigious medical schools including Harvard Medical School and University of Pennsylvania School of Medicine. He has also led Radiation Therapy Resident Programs at the University of Pennsylvania and Allegheny University Hospitals.
“Electronic Brachytherapy is quickly becoming a sought after treatment option in the field of radiation oncology,” said Dr. Goodman. “The Xoft System’s mobile capabilities and innovative delivery technology help address some of the most challenging issues associated with comprehensive cancer care in today’s clinical environment. I look forward to joining iCAD’s esteemed board members in their commitment to improving upon and expanding the availability of advanced treatment options that play such a critical role in the lives of cancer patients.”